Amoxicillin

Amoxicillin is an antibiotic of the penicillin family, classed as an aminopenicillin. It kills or inhibits many bacteria by interfering with the construction of their cell walls, and it is taken by mouth as well as given by injection in some settings. It is among the most commonly prescribed antibacterial drugs worldwide, used for respiratory, ear, sinus, skin, urinary and dental infections, and as part of combination regimens for other conditions. Its importance comes from the combination of a broad spectrum, good oral absorption, a favourable safety profile for most patients, and a low cost, which together have made it a standard item in health systems and in the World Health Organization's essential medicines guidance.

This entry describes amoxicillin as a chemical compound and as a clinical drug. It begins with its molecular structure and mechanism of action, then covers its antibacterial spectrum, clinical use, pharmacokinetics, adverse effects and drug interactions. It then turns to bacterial resistance, which is the main threat to the drug's future usefulness, and to the history of its discovery and its manufacture. The final sections address its formulations, its role in public health and its patent and market history, along with open questions about dosing duration and stewardship.

Chemical structure and properties

Core structure

Amoxicillin is a semisynthetic antibiotic built on the penicillin nucleus. Its IUPAC name places sulfur and nitrogen in a fused bicyclic framework, and that framework is the shared core of all penicillins (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. The four-membered β-lactam ring contains three carbon atoms and one nitrogen atom, and it is this strained ring that is chemically reactive and gives the drug its antibacterial action Its chemical structure, similar to penicillin, is characterized by a beta-lactam ring, a four-sided ring consisting of three carbons and one nitrogen atom.. The second ring, a five-membered thiazolidine containing sulfur, is fused to it. The anhydrous molecule has the formula C16H19N3O5S and a molar mass of roughly 365.4 g/mol its chemical formula is C16H19N3O5S, giving it a molecular mass of 365.4042 g/mol..

The p-hydroxyphenyl side chain

The feature that separates amoxicillin from its parent compounds is the side chain attached at the 6-amino position. Chemically, it is the para-hydroxy counterpart of ampicillin, prepared by acylation of 6-APA with p-hydroxyphenylglycine. The extra phenolic hydroxyl makes the side chain more polar than ampicillin's plain phenyl ring. This change is generally linked to amoxicillin's better oral absorption, but it does not greatly alter the spectrum: its antibacterial spectrum is nearly identical with that of ampicillin. The free amino group on the side chain is what broadens activity against Gram-negative bacteria compared with natural penicillins The free amino group on this molecule enhances activity against gram-negative bacteria in comparison with natural penicillins, such as penicillin G.

Stereochemistry

Amoxicillin has four defined stereocentres: three in the penicillin core and one at the α-carbon of the side chain Defined Stereocenters 4 / 4. The side-chain carbon is the one that determines biological activity. The drug is the D-configured isomer, and the L-epimer is generally considered far less potent. Patent claims for related compounds specify the D-configuration at this same carbon, which shows how central the handedness is to the chemistry The compound of the structure having the D-configuration at the carbon atom marked with an asterisk.. For this reason, synthesis and purification must preserve the correct configuration, since a racemic or epimerised product would contain a substantial fraction of less active material.

Acid stability

Amoxicillin survives the acidic environment of the stomach far better than earlier penicillins. Like ampicillin, it is resistant to acid, susceptible to alkaline and β-lactamase hydrolysis. Natural penicillins such as penicillin G are destroyed by gastric acid, which is why they must be given parenterally. Reviews note that amoxicillin has enhanced stability towards gastric juices compared to other β-lactam antibiotics. This acid tolerance allows a meaningful fraction of an oral dose to reach the small intestine, where it is absorbed through the digestive tract.

Salt and hydrate forms

Commercial amoxicillin is most often supplied as the trihydrate, in which three water molecules are incorporated into the crystal lattice. The amoxicillin molecular formula is C16 H19 N3 O5 S•3H2 O, and the molecular weight is 419.45. Dosing labels must therefore state which form is meant: capsules are labelled by their 500 mg amoxicillin as the trihydrate. The solid is a white to off-white free flowing crystalline powder.

Solubility is limited. The material is slightly soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in fatty oils. It dissolves in dilute acids and dilute solutions of alkali hydroxides. Reported figures conflict: one supplier lists Soluble in water at 3.4mg/ml., while another source gives a value of 4 g/ml at pH 3.5 – 5.5 Solubility in water 4 g ml -1 pH 3.5 – 5.5. The discrepancy likely reflects differing units and conditions. For regulatory purposes, a biopharmaceutical review found that amoxicillin doses up to 875 mg belong to BCS class I, whereas 1000 mg belongs to BCS class II, which affects whether bioequivalence studies can be waived. Handling also matters: purer, enzymatically produced trihydrate was found to dissolve less readily, and reduction of particle size is a well-known approach to improve solubility.

Mechanism of action

Targets: penicillin-binding proteins

Amoxicillin acts through its antibiotic β-lactam ring, the same reactive core it shares with penicillin and the wider β-lactam class. Its main targets are membrane-associated enzymes called penicillin-binding proteins (PBPs). The drug competitively blocks PBP1 and other high-molecular-weight PBPs Amoxicillin competitively inhibits penicillin-binding protein 1 and other high molecular weight penicillin binding proteins.

These enzymes build the peptidoglycan layer of the cell wall in two linked steps. Glycosyltransferases extend the sugar backbone, and transpeptidases join short peptide side chains across neighbouring strands. The transpeptidase reaction works like other enzymatic catalysis in that an active-site serine attacks a peptide bond at the terminal D-alanine residues of a side chain, forming an acyl-enzyme intermediate that is then attacked by an amino group from a neighbouring strand. The strained β-lactam ring of amoxicillin mimics that substrate. The active-site serine acylates the drug in the same way, but the resulting acyl-enzyme is hydrolysed extremely slowly, so the enzyme is effectively taken out of service. This is the sense in which the binding is described as essentially irreversible.

Lysis in growing cells

Peptidoglycan is not static. Growing bacteria continually remodel their walls, and they also carry endogenous autolytic enzymes that cut the wall to allow insertion of new material. When cross-linking fails, the wall loses strength while those autolysins remain active. In actively dividing bacteria, this leads to weakening of the cell wall, activation of autolytic enzymes, osmotic instability, and cell lysis. The internal turgor pressure of a bacterium, which is several atmospheres, can then no longer be contained, and the cell ruptures. Because the damage accumulates and cannot be repaired while the drug stays bound, the effect is bactericidal rather than merely bacteriostatic.

The killing is also time-dependent. Efficacy correlates best with the duration for which free drug concentration remains above the organism's MIC, rather than with very high peak concentration. This explains why dosing schedules are designed to keep unbound drug above the minimum inhibitory concentration for a sufficient fraction of each interval.

Selectivity for bacteria

Human and other mammalian cells contain no peptidoglycan wall and do not produce PBPs. The drug's target is therefore absent from host tissue, which accounts for its low direct toxicity to human cells. Most clinically important adverse effects arise from immune reactions or changes in the gut microbiota rather than from direct damage to host cells.

Gram-positive and Gram-negative organisms

The two major bacterial groups differ mainly in the architecture of the envelope, a distinction revealed by the Gram stain. Gram-positive bacteria have a thick peptidoglycan layer on the outside of the cytoplasmic membrane. Amoxicillin diffuses through this porous layer and reaches PBPs anchored in the membrane with little obstruction.

Gram-negative bacteria have only a thin peptidoglycan layer, which lies in the periplasm beneath an outer membrane containing lipopolysaccharide. The outer membrane is a lipid barrier that hydrophilic molecules such as amoxicillin cross poorly. Passage therefore depends largely on water-filled porin channels, and the number and type of porins a species expresses strongly influence how much drug reaches its PBPs. Its spectrum is broader than natural penicillin because it penetrates the outer membrane of some Gram-negative organisms more effectively. This is why amoxicillin reaches several Gram-negative species that natural penicillin cannot, while other Gram-negative organisms remain poorly affected. Penetration is only one factor, however; the same porins and efflux systems that control entry also shape resistance, a topic addressed elsewhere.

Antibacterial spectrum and clinical indications

Amoxicillin is a broad-spectrum agent within the aminopenicillins. Its activity is strongest against Gram-positive cocci, especially streptococci and enterococci, and it adds some Gram-negative coverage beyond that of penicillin V. In vitro studies from the 1970s reported activity against most isolates of Proteus mirabilis and Escherichia coli, and it was found to be about twice as active as ampicillin against Salmonella but less active against Shigella. Its coverage of Streptococcus pneumoniae is weaker than that of benzylpenicillin, and penicillin-resistant pneumococci are generally resistant to amoxicillin too, although higher doses may help in some cases. Other organisms within its range include Haemophilus influenzae (beta-lactamase-negative strains), Listeria monocytogenes, and Neisseria gonorrhoeae, which accounts for its use in gonorrhoea in some regimens.

Typical indications

In the United States, the FDA label restricts use to infections caused by susceptible isolates of selected bacteria, specifically beta-lactamase-negative ones. Within that limit, the main indications are ear, nose and throat infections, such as otitis media, tonsillitis, pharyngitis and acute bacterial sinusitis; lower respiratory tract infections, including community-acquired pneumonia and bronchitis; urinary tract infections; and skin and skin-structure infections. Dental infections are a common clinical use, and amoxicillin is routinely used in the prevention of infection before certain dental procedures and in the management of odontogenic infections such as dental abscesses, where it is often combined with measures to drain the source. Amoxicillin is also used off-label in some other settings, including early Lyme disease.

Helicobacter pylori eradication

Amoxicillin is a core component of the regimens used to eradicate Helicobacter pylori, a Gram-negative bacterium that colonises the gastric mucosa. The standard first-line combination in regions with low clarithromycin resistance is a proton-pump inhibitor, given twice daily, with clarithromycin 500 mg and amoxicillin 1 g, both twice daily, for 14 days. The proton-pump inhibitor lowers gastric acidity, which helps the antibiotics remain active in the stomach and improves their concentration in the gastric mucosa. Where the patient is allergic to penicillin, metronidazole is substituted for amoxicillin. Rising clarithromycin resistance has reduced the success of this triple therapy, so many guidelines now favour bismuth-containing or non-bismuth quadruple regimens, or dual therapy with a potassium-competitive acid blocker and high-dose amoxicillin in some settings. Susceptibility-guided therapy is considered the ideal approach where testing is available.

Organisms not covered and the role of testing

Amoxicillin is inactive against bacteria that produce beta-lactamases, enzymes that hydrolyse the beta-lactam ring. Many Staphylococcus aureus isolates and some strains of H. influenzae, Moraxella catarrhalis, E. coli and Klebsiella produce such enzymes, and Pseudomonas aeruginosa is intrinsically resistant. Organisms that lack a peptidoglycan wall, such as Mycoplasma, are not affected, because the drug's target is absent, and intracellular organisms such as Chlamydia are also outside its usual range. Combining amoxicillin with clavulanic acid, as in co-amoxiclav, protects the drug from many of these enzymes and widens its spectrum. Because resistance rates vary by region, by organism and by individual patient history, culture and antimicrobial susceptibility testing remain the basis for choosing amoxicillin when the infection is severe, recurrent or in a setting of high resistance.

Pharmacokinetics and dosing

Amoxicillin is absorbed readily from the gut, and its oral bioavailability is high. Early studies in young, healthy male volunteers reported bioavailability of 77–93%, and a widely cited summary gives about 95%, though another compilation lists 60%, so reported values vary with the study design and source. The hydroxyl group that distinguishes it from ampicillin makes the molecule more lipid-soluble, which is usually linked to its better absorption. The drug also resists the acidity of the stomach, so a meaningful share of each dose reaches the small intestine intact. In a comparative study, amoxicillin produced a peak blood concentration more than double that of ampicillin after equal doses. Peak plasma levels are reached relatively quickly, with a time to peak plasma concentration of approximately 1.5 hour, and exposure rises in proportion to dose across the usual therapeutic range, from 250 to 3000 mg.

Food has little effect on absorption. One review notes that bioavailability appears to be improved when amoxicillin is taken fasting, but clinical trials given without regard to meals have shown efficacy. Regulatory bioequivalence guidance states that absorption is not influenced by simultaneous food intake, and paediatric labelling commonly allows the drug to be taken with or without food.

Once absorbed, amoxicillin spreads widely. It distributes widely into body tissues and fluids, including respiratory secretions, middle ear fluid, urine, bile, and skin tissues. Protein binding is low, so protein binding is relatively low compared with many other antibiotics, leaving a substantial unbound, active fraction. Penetration into the cerebrospinal fluid is limited unless the meninges are inflamed. Middle-ear penetration is clinically important because of acute otitis media. In a study of children, the estimated middle ear fluid concentration peak occurred 3.0 h after the dose, and concentrations were lower when the infection was viral: geometric mean concentrations were lowest in virus-infected children (2.7 μg/ml), compared with 5.7 μg/ml in children with bacterial-only infection.

Elimination is mainly renal. Amoxicillin is primarily eliminated by the kidneys through glomerular filtration and tubular secretion, and hepatic metabolism plays only a small role. Its half-life is short: its elimination half-life ranges from 0.7 to 1.4 hours in patients with normal renal function and 7 to 10 hours in patients with impaired renal function. Because the drug is cleared through the kidneys, impaired renal function markedly prolongs exposure, and dose adjustment may be required in significant renal impairment. Pharmacokinetic work in patients with varying degrees of kidney impairment found a linear relationship between beta of amoxicillin and creatinine clearance, which the authors judged useful for setting dosing regimens. The short half-life also explains why the drug is usually given several times a day, and why maintaining effective concentrations depends on prolonged absorption.

Dosing depends on age, body weight, infection type and severity, and kidney function. For adults and children weighing 40 kg or more, the usual oral regimens are 250 to 500 milligrams (mg) every 8 hours, or 500 to 875 mg every 12 hours. For children under 40 kg, dosing is calculated per kilogram: the usual dose is 20 to 40 milligrams (mg) per kilogram (kg) of body weight per day, divided and given every 8 hours, or 25 to 45 mg per kg of body weight per day, divided and given every 12 hours. Infants younger than three months are generally dosed at 30 mg per kg of body weight per day, divided and given every 12 hours. Treatment length also varies, from 7 to 10 days to several weeks, depending on the infection.

Adverse effects, allergy and drug interactions

Most adverse effects of amoxicillin are mild, and gastrointestinal symptoms are the most familiar. Nausea and diarrhoea become more likely when the drug is combined with probenecid, because the combination keeps amoxicillin in the blood for longer. If you take probenecid and amoxicillin together, there's a higher risk of developing amoxicillin side effects, such as new or worsening nausea, vomiting, or diarrhea. Diarrhoea during or after treatment should not be dismissed as routine. Nearly every antibacterial agent has been linked to pseudomembranous colitis caused by Clostridioides difficile, and amoxicillin-clavulanate is included in that list. Pseudomembranous colitis due to Clostridium difficile has been reported with nearly all antibacterial agents, including Amx/Clv.

Rash and infectious mononucleosis

The best-documented rash problem involves patients with Epstein-Barr virus infection. Eruptions usually emerge about a week after the drug is started and fade within roughly seven days. The rash, a diffuse pruritic maculopapular exanthem that often involves the palms and soles, typically appears 7 to 10 days after antimicrobial administration and resolves within a week. Estimates of how often this happens have fallen over time. Early reports suggested almost every patient was affected, but later work gives a much lower figure. In a paediatric cohort, amoxicillin produced rash in about 29.5% of treated children, far below the roughly 90% recorded for ampicillin in earlier studies. Amoxicillin was associated with the highest incidence of antibiotic-induced rash occurrence (29.5%, 95% confidence interval: 18.52–42.57), but significantly lower than the 90% rate reported for ampicillin in past studies.

The mechanism remains disputed. Some authors treat the rash as a non-allergic, immune-mediated reaction. Others have found evidence of genuine drug sensitisation in patients with the virus, and they note that viral infections enhance the risk of drug allergic reactions. The two views are not yet reconciled, so a rash during mononucleosis does not by itself settle whether a patient is truly allergic.

Hypersensitivity and anaphylaxis

True penicillin allergy is much rarer than the number of people who carry the label. Although a large number of patients are labeled as allergic to penicillin, more than 95% of them can tolerate penicillin after an appropriate evaluation. Immediate reactions are IgE-mediated. They begin quickly, often within an hour, and can range from urticaria to angioedema and anaphylaxis, with the latter driven by IgE antibodies against drug cause mast cell degranulation. In a prospective series of 49 patients with confirmed amoxicillin hypersensitivity, anaphylaxis was the most common presentation, which underlines why a history of severe reaction matters.

Cross-reactivity between penicillins is best understood through the side chain. Allergic responses are thought to target antibodies against metabolites of the penicillin molecule, specifically the R 1 side chains of the beta-lactam ring. Amoxicillin shares a side chain with ampicillin, so patients allergic to one are at higher risk with the other. Cross-reactivity with cephalosporins is greatest when side chains are similar, and it is low for third- and fourth-generation agents. Cross-reactivity between penicillin and cephalosporin drugs occurs in about 2% of cases, less than the 8% reported previously.

The consequences of a penicillin allergy label extend beyond the individual. Patients with such labels are more often given broader-spectrum drugs, and a penicillin allergy is associated with higher rates of Clostridiodes difficile and methicillin-resistant Staphylococcus aureus, along with longer and more costly hospital stays. Allergy assessment, including direct amoxicillin challenge for low-risk patients, is therefore part of antimicrobial stewardship.

Interactions

The most clinically documented interaction involves probenecid, a drug used for gout. Probenecid reduces the kidney's secretion of amoxicillin into urine, so blood concentrations rise and last longer. Probenecid decreases the renal tubular secretion of amoxicillin and can result in increased and prolonged blood levels of amoxicillin. Labelling for the combination advises against routine co-administration. Allopurinol, another gout medicine, also matters: concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone.

The effect of amoxicillin on oral contraceptives is less settled. The proposed mechanism is indirect. Estrogen is recycled through the gut by bacteria, so a disturbed gut microbiome could lower hormone reabsorption. However, this mechanism is primarily theoretical, and clinical studies have shown conflicting results regarding the actual clinical significance of this interaction. Some reviews found no significant interaction, while others associated antibiotic use with unintended pregnancy, so guidance varies between prescribers and national bodies.

Bacterial resistance

Enzymatic inactivation by β-lactamases

The most widespread route to resistance is the production of β-lactamases, which hydrolyse the amide bond of the β-lactam ring and leave the drug unable to reach its targets. The major mechanism of resistance to β-lactam antibiotics is the bacterial production of β-lactamases, which hydrolyze the amide bond of the β-lactam ring of these drugs to render them ineffective. The enzymes fall into four classes (A to D). Enzymes from classes A, C, and D are serine hydrolases that act through a covalent, acyl-enzyme intermediate that is subsequently hydrolyzed by an activated water, whereas enzymes from class B are zinc metalloenzymes. Because amoxicillin is most vulnerable to the class A enzymes, the drug was paired with a second molecule. Clavulanate was added to amoxicillin to give the combination drug greater activity against those organisms that produce non-group 1 (class A) β-lactamases.

Clavulanic acid itself has little antibacterial action. Its value lies in its mechanism: it functions as a "suicide inhibitor" of serine β-lactamases, forming a covalent, irreversible complex with the enzyme's active site. The combination therefore has activity against amoxicillin-resistant strains when the mechanism of resistance is due to production of beta-lactamases susceptible to inhibition by clavulanic acid. The protection has limits. Chromosomally encoded beta-lactamases produced by Enterobacter spp., Citrobacter spp., Serratia spp., and Pseudomonas spp., are not inhibited by clavulanic acid, and clavulanic acid inhibits most extended-spectrum beta-lactamases (ESBLs) in vitro, but in vivo its activity is limited. A single substitution, K234R, in one class A enzyme family is associated with decreased potency of the inhibitor clavulanic acid. In Campylobacter, resistance to the combination is rare; in one French national reference series from 2017 to 2022 it accounted for only 0.1% of isolates.

Alteration of penicillin-binding proteins

Resistance can also arise when the target itself changes. In Streptococcus pneumoniae, the targets of amoxicillin - PBP1a, PBP2x, PBP2b, can be altered to allow bacteria to confer resistance to the drug. Changes in the transpeptidase domain are linked to rising minimum inhibitory concentrations. In one collection of isolates, a single substitution in PBP1a was enough to account for amoxicillin resistance. In Helicobacter pylori, several PBP1A mutations act in combination: the more mutations present, the weaker the binding of amoxicillin to PBP1A, which is consistent with changes to the drug's access route as well as to the binding site. Bacteria can also raise resistance by producing more PBP molecules, so that the antibiotic cannot inhibit all of these molecules, allowing bacterial cell wall synthesis to continue uninterrupted.

Reduced permeability and efflux

In Gram-negative organisms, the outer membrane is a barrier that the drug must cross through porin channels. Reduced drug uptake can be due either to a reduction or alteration in the porin channels used by β-lactams to cross the outer membrane, or to the presence of efflux pumps that can actively extrude β-lactams from the periplasmic space. In Moraxella catarrhalis, downregulation of this porin reduces the bacteria's permeability to amoxicillin and significantly increases the minimum inhibitory concentration. The two mechanisms often work together. A low affinity PBP3 can also be found in strains expressing a β-lactamase, and both mechanisms can cooperate to increase the resistance, and in Neisseria a porin and an efflux pump are among the non-PBP loci that contribute to β-lactam resistance.

Spread through plasmids and gene transfer

Resistance genes are frequently carried on mobile elements that move between cells. Laboratory experiments have confirmed that plasmids isolated from AR outbreaks in hospitals can transfer by conjugation between bacterial species. In one example, conjugation transferred plasmids with clinically relevant ESBL-encoding genes bla_OXA-48, bla_NDM-1, bla_KPC-2, and bla_SHV-1 from K. pneumoniae hospital isolates to laboratory E. coli. Transduction by bacteriophages can also move these genes; in Staphylococcus aureus it can be efficient enough to surpass the transduction frequency of a chromosomal methicillin resistance gene. Exposure to amoxicillin itself can promote the process. In E. coli, the chromosomal beta-lactamase gene ampC is multiplied and results in an 8–13 kb contig. This contig is comparable to a transposon, which can move between cells. Plasmid-borne enzymes can also be favoured under drug pressure: in one study, plasmid-encoded KPC-2 was more effective in protecting neighbouring sensitive cells, and in the presence of a β-lactam antibiotic, strains with non-cooperative plasmids were efficiently outcompeted.

Selection pressure and surveillance

Wide use of these drugs is the main driver of resistance. The result is that because of their widespread use, bacterial resistance to these drugs now represents a threat to antimicrobial therapy. Antibiotic exposure also affects the spread of resistance itself: both chromosomal- and plasmid-borne ARGs can transfer by transduction, and antibiotics likely increase the rates of transfer. Because of this, resistance trends are tracked through laboratory and reference networks. The growing resistance to amoxicillin (AMX)—one of the main antibiotics used in Helicobacter pylori eradication therapy—is an increasing health concern. Routine susceptibility monitoring of this kind is what allows prescribers and public-health bodies to notice shifts early and revise guidance.

Discovery and history

Penicillin began as a laboratory accident. On September 3, 1928, Alexander Fleming found that a culture plate of Staphylococcus aureus had been contaminated by a mould, and the bacteria around it had stopped growing. Fleming, working with two young researchers, failed to stabilize and purify penicillin. However, he did point out that penicillin had clinical potential, both as a topical antiseptic and as an injectable antibiotic, if it could be isolated and purified. Fleming's own interest stayed mostly on penicillin's potential use as a topical antiseptic for wounds and surface infections for about a decade.

The drug became a therapy through work at Oxford. Florey and Chain demonstrated in 1940 that penicillin could be used as a therapeutic agent to fight a large number of bacterial diseases. Clinical use followed in 1941, and Florey and Chain succeeded in developing methods for mass production of penicillin, which was just in time to treat the many wounded soldiers during World War II. Production was expanded through cooperation between the United States and Britain, and researchers in the Netherlands produced penicillin using their own production methods and marketed it in 1946, which eventually increased the penicillin supply and decreased the price. The three scientists shared the 1945 Nobel Prize in Physiology or Medicine.

Through the 1950s, the beta-lactam family remained small. In the 1950s, the entire beta-lactam family of antibiotics included only penicillin G and penicillin V. Those early penicillins acted mainly on Gram-positive organisms, and the search for agents against Gram-negative bacteria led to the aminopenicillins. The origin of amino penicillins lies in ampicillin, discovered in 1961. The aminopenicillins were the first penicillins that had activity against some gram-negative organisms. The added amino group carries a charge that let the molecule act against Gram-negative pathogens such as Escherichia coli and Haemophilus influenzae.

Amoxicillin was developed as a refinement of ampicillin. Amoxicillin differs from ampicillin by the presence of a hydroxyl group on the phenyl side chain. Sources disagree on its dates. One reference states that amoxicillin was discovered by researchers at the Beecham pharmaceutical laboratories in 1962 and marketed about a decade later under the trade name of Amoxil®. Another gives 1972 as the year of discovery at Beecham Research Laboratories, and records US approval on Jan 18, 1974. Its practical advantage was oral absorption: it is much better absorbed when given orally, achieving blood concentrations approximately twice as high as those obtained with ampicillin. That property made it a convenient oral alternative to ampicillin, although the speed of its uptake in clinical practice is not documented in the sources reviewed here.

Prescribing patterns changed as use grew. Broad-spectrum penicillins, the aminopenicillins, were developed in the 1960s. A later US patent on amoxicillin formulations recorded that organisms highly susceptible when ampicillin was first used in the early 1960s had become increasingly resistant, and that from 30% to 50% of E. coli were insensitive by that time. Resistant strains of Salmonella (plasmid mediated) have been recovered with increasing frequency in various parts of the world. The wide use of penicillins from the 1940s onward therefore became a central reason for the later emphasis on careful antibiotic use. Some bacteria have developed resistance to penicillin, highlighting the importance of using antibiotics carefully.

Manufacturing and chemical synthesis

Industrial amoxicillin is made in two main stages: first a penicillin core is prepared, and then a side chain is attached to it. The penicillin itself comes from fermentation of Penicillium cultures. The core is then freed by enzymatic cleavage. PGa catalyses the hydrolysis of penicillin G to produce 6-aPa, which is then chemically modified to create amoxicillin. The enzyme involved is penicillin G acylase, which works through hydrolysis of the side chain.

The side chain, a p-hydroxyphenylglycine unit, can be attached by two broad routes. The older chemical route acylated 6-APA using a mixed anhydride formed from ethyl chloroformate and a protected p-hydroxyphenylglycine, with the protecting groups later removed by catalytic hydrogenation. Other chemical variants used silylated 6-APA with an acid chloride hydrochloride. These methods depend on hazardous reagents, and one account describes them as environmentally burdensome and require the use of hazardous chemicals such as pyridine, phosphorous pentachloride and nitrosylchloride. The enzymatic route couples 6-APA with a p-hydroxyphenylglycine methyl ester under catalysis by the enzyme. In one-pot versions, a cascade reaction combining the enzymatic hydrolysis of Penicillin G potassium salt with the kinetically controlled enzymatic coupling of in situ formed 6-aminopenicillanic acid yields the product using a single enzyme. Kinetic control has a cost: there are two side reactions: PHPGME hydrolysis to p-hydroxyphenyl glycine and amoxicillin hydrolysis, both of which lower the yield. One two-step variant added zinc sulfate to remove the product as a complex and push the equilibrium forward, reaching a yield of 76.5% after optimisation. Immobilised enzyme on solid supports is also widely studied to allow repeated use.

Downstream processing is largely a matter of crystallisation. Amoxicillin's metastable zone is generally between pH1.5 and 8.5, and conventional processes adjust the solution to the isoelectric point using acid or alkali. Local pH excursions are a practical problem, since they can cause the degradation of amoxicillin, and then produce impurities, influence crystal quality. The commercial solid is usually crystallised near pH 4.7, and the trihydrate is preferred because it is the most stable hydrate; the sodium salt, by contrast, is highly hygroscopic, while trihydrate is not hygroscopic. Impurity control is also chemically specific: one study correlated rising pH levels and declining 4-hydroxyphenylglycine (4-HPG) concentration, showing how process conditions shape the impurity profile. Recent work has explored greener alternatives; one malic-acid-assisted process reported a yield of 61.82% and a purity of 99.21% under optimised conditions.

Final product specifications are set by pharmacopoeias. Amoxicillin trihydrate and its salts have been monographed in several pharmacopoeias such as the International Pharmacopoeia, the British Pharmacopoeia, and the US Pharmacopeia. Manufacturers must therefore control impurities and residual solvents to these standards. Solvent recovery has been a particular burden in salt production, where one patent noted that older processes required the incineration of several kilograms of solvents per kilogram of sodium amoxicillin.

Quality and supply are closely linked at scale. Amoxicillin is made by relatively few companies, and raw materials for Amoxicillin are largely sourced overseas. The 2022–2023 shortages involved the three largest suppliers, Hikma, Sandoz and Teva, and were concentrated in oral suspensions, which are harder to manufacture than capsules. Although demand surges were the apparent trigger, a pharmacist at the American Society of Health-System Pharmacists noted that most of the 260 drug shortages listed in the ASHP database can be traced to quality control issues. Manufacturing practice also differs by country: the process for producing amoxicillin by an enzymatic method is basically popularized in China, whereas other producers use chemical routes. The US Food and Drug Administration ended the amoxicillin suspension shortage in May 2025.

Formulations, public health and access

Amoxicillin is supplied in several oral and injectable forms, and the choice among them depends on the patient's age, the setting and the severity of illness. The World Health Organization's 21st Model List of Essential Medicines (2019) lists solid oral doses of 250 mg and 500 mg, expressed as the trihydrate, along with powders for oral liquid at 125 mg and 250 mg per 5 mL and injectable powder in vials of 250 mg, 500 mg and 1 g (as the sodium salt). The list gives powder for oral liquid at 125 mg (as trihydrate)/5 mL and 250 mg (as trihydrate)/5 mL, solid oral dosage forms of 250 mg and 500 mg (as trihydrate), and powder for injection of 250 mg, 500 mg and 1 g (as sodium) in vials. Amoxicillin is also combined with clavulanic acid in tablets and liquids; in 2021 a higher-strength 7:1 tablet (875 mg + 125 mg) was recommended for adults with community-acquired pneumonia and intra-abdominal infections. In 2021, a higher strength formulation of amoxicillin + clavulanic acid in a 7:1 ratio (875 mg + 125 mg) was recommended for inclusion on the EML for treatment of community-acquired pneumonia and intra-abdominal infections in adults.

For children, the dispersible tablet has become the central product in low-resource settings. In 2014, WHO published its recommendations for home treatment of pneumonia, establishing dispersible amoxicillin as the recommended first line treatment for pneumonia in children under five. The agency also recommends amoxicillin 250 mg dispersible tablets as the most convenient formulation to treat childhood pneumonia in community settings, and especially in remote areas where no reliable sources of clean water and electricity are available. Tablets are cheaper and lighter to transport than bottled suspensions, and they avoid the stability problems of liquids. The reconstituted powder suspension needs refrigeration to keep its potency, and a study of suspensions sold in low- and middle-income countries noted that many patients there would not be expected to store them under the specified conditions. This gap between label instructions and household storage is one reason why solid forms are favoured in these settings.

Amoxicillin's place on the essential medicines list reflects its cost, its narrow-spectrum profile against common pathogens, and its role in primary care. The WHO places amoxicillin in its Access group antibiotics category, which is intended for first-choice empiric treatment of common infections. The drug has been on the list since the agency first included it, and national lists in many countries follow the same logic. In the United States, in 2023, it was the 23rd most commonly prescribed medication in the United States, with more than 23 million prescriptions. Most supply is available as a generic medication, which keeps prices low but also means that many manufacturers compete on thin margins.

That structure has produced recurring supply problems. In the United States, the Food and Drug Administration acknowledged a shortage in 2022 and listed 23 amoxicillin products on its current drug shortages page due to increased demand for the drug. The shortage spread beyond the children's suspension: it now encompasses oral capsules, tablets, and chewable tablets as well, according to the American Society of Health-System Pharmacists. Manufacturers gave several reasons. Sandoz, a major supplier, said that significant demand in the United States, Europe and Canada prompted a "supply situation" that has been exacerbated by the impact of the pandemic, manufacturing constraints and the energy crisis. Shortages were reported in other countries as well, and lack of availability has also been reported in Ireland, Malaysia, Romania, and Australia. In Europe, the European Medicines Agency later recorded the shortage as resolved.

Prescribing is governed by antibiotic stewardship programmes in hospitals and primary care, and by national treatment guidelines that set first-choice drugs, doses and durations. These measures aim to limit unnecessary use, which accelerates resistance, and they are monitored through surveillance of prescribing and resistance trends. Because amoxicillin is so widely used, stewardship decisions about it have large effects on population-level resistance and on the stability of the supply chain.

Evidence, open questions and future use

The strongest recent evidence for amoxicillin concerns treatment duration. In a two-centre, blinded randomised trial of previously healthy children with pneumonia who did not need hospital admission, five days of high-dose amoxicillin was compared with ten days, and clinical cure at 14 to 21 days was comparable, at 85.7% for the short course and 84.1% for standard care. A meta-analysis of three trials covering 789 children aged 6 months to 10 years found no differences between 5-day and 10-day therapy regarding clinical cure, and graded the certainty of this evidence as moderate. A later systematic review of seven RCTs that studied a total of 8590 children reported that a three-day amoxicillin course was non-inferior to courses of five to ten days, and that shorter treatment was associated with fewer non-severe adverse events.

The picture is not uniform. A randomised trial in Israeli young children found a higher rate of treatment failure (40%) in subjects treated for only 3 days, and a study of outpatients aged 6 to 59 months concluded that a 5-day course with high-dose oral amoxicillin was not inferior to a 10-day course. The 3-day regimen may be associated with an unacceptable failure rate. The evidence therefore supports five days more firmly than three. A larger US-sponsored trial, SCOUT-CAP, is designed as a superiority study comparing five with ten days of beta-lactam therapy in children who have already improved clinically, and if superior to standard course therapy, short course therapy could reduce antibiotic exposure among young children.

Dosing in special populations remains less settled. Pharmacokinetic studies in obese and bariatric adults have consistently shown lower amoxicillin exposure than in people of normal weight, and in one systematic review 70% of morbidly obese adults were considered underdosed under the dosing studies examined. The same review concluded that more PK studies are needed to confirm the optimal dose of AMX for obese patients, particularly in children. A separate review proposed a higher dose of 1 g every eight hours for obese adults and favoured liquid formulations for bariatric patients, but this was a reviewer's recommendation rather than an established guideline.

In critical illness, the central question is whether prolonged infusion yields better drug exposure and outcomes. Most of this evidence comes from beta-lactams in general rather than amoxicillin specifically, so applying it to amoxicillin is an inference. Prolonged infusion improves target attainment by maintaining concentrations above the MIC, and the BLING III trial demonstrated significantly higher clinical cure rates with continuous infusion. Earlier small trials, however, were limited because most trials utilized inconsistent antibiotic doses and recruited only small numbers of heterogeneous patient groups.

Diagnostic testing is a second line of inquiry. A meta-analysis of thirteen studies found that CRP-POCT significantly reduced immediate antibiotic prescribing at the index consultation compared with usual care, but it was accompanied by significantly higher rates of re-consultation within 30 days. Results from other settings are less favourable. The ProACT trial in the United States found no overall reduction in antibiotic use, and the authors attributed much of this to clinician adherence of 64.8%, lower than in earlier European trials. Because respiratory tract infections are the most common reason for inappropriate antibiotic prescribing in primary care, which is a major driver for antibiotic resistance, the value of such tests for stewardship is a live question.

Several issues remain open. These include whether the optimal duration varies by infection type, whether amoxicillin or an amoxicillin-clavulanate combination is the better choice for particular sites such as sinusitis or dental infections, and how resistance surveillance in communities and hospitals should inform local prescribing. Future use will also depend on how resistance evolves: new beta-lactamase inhibitor combinations and non-beta-lactam alternatives are under development, and their role relative to amoxicillin will shift as susceptibility patterns change.

References

1. Amoxicillin - an overviewsciencedirect.com
2. Amoxicillin Antibiotic Structure Molecular Model built with Indigo Instrument (indigoinstruments.com) Atoms & Bonds.indigoinstruments.com
3. Amoxicillin - Citizendiumcitizendium.org
4. Amoxicillinchemicalbook.com
5. AMOXICILLINprecision.fda.gov
6. Methoxymethyl 6-[D-2,2-dimethyl-4-(4-hydroxyphenyl)-5-oxo-1-imidazolyl]penicillanateimage-ppubs.uspto.gov
7. Amoxil: Package Insert / Prescribing Informationdrugs.com
8. Amoxicillin trihydratechemicalbook.com
9. Amoxicillin trihydrate (Molecular formula: C16H19N3O5S, 3H2O)researchgate.net
10. Amoxicillin Trihydrate - Journal of Pharmaceutical Sciencesjpharmsci.org
11. Micronized amoxicillinimage-ppubs.uspto.gov
12. Enzymatic preparation of 6-D-(-)-.alpha.-amino-.alpha.-(p-hydroxyphenylacetamino)penicillin acidimage-ppubs.uspto.gov
13. Amoxicillin: Uses, Interactions, Mechanism of Actiongo.drugbank.com
14. Pharmacology of Amoxicillinpharmacologymentor.com
15. Amoxicillin - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
16. Amoxicillinantimicrobe.org
17. Amoxicillinstatpearls.com
18. CME Activitystatpearls.com
19. Amoxil (amoxicillin) dosing, indications, interactions, adverse effects, and morereference.medscape.com
20. Amoxicillin - an overviewsciencedirect.com
21. Amoxicillin: A Broad Spectrum Antibiotic.researchgate.net
22. Proton pump inhibitor‐ and clarithromycin‐based triple therapies for Helicobacter pylori eradication - PMCpmc.ncbi.nlm.nih.gov
23. Helicobacter pylori eradication protocolsen.wikipedia.org
24. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistancencbi.nlm.nih.gov
25. Amoxicillinrehabmypatient.com
26. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage - ScienceDirectsciencedirect.com
27. Amoxicillin: Action, Activity, Pharmacokinetics, and Interactions - Biology Insightsbiologyinsights.com
28. Notes on the Design of Bioequivalence Study: Amoxicillinextranet.who.int
29. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis mediajournals.lww.com
30. Pharmaceutical compositions for the treatment of Helicobacter pyloriimage-ppubs.uspto.gov
31. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function - PubMedpubmed.ncbi.nlm.nih.gov
32. Amoxicillin (oral route) - Side effects & dosage - Mayo Clinicmayoclinic.org
33. Amoxicillinen.wikipedia.org
34. Development and Validation of Limited-Sampling Strategies for Predicting Amoxicillin Pharmacokinetic and Pharmacodynamic Parameters - PMCpmc.ncbi.nlm.nih.gov
35. How much amoxicillin should I give my child?singlecare.com
36. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media - PubMedpubmed.ncbi.nlm.nih.gov
37. Amoxicillin: Mechanism of action, Pharmacokinetics, and Therapeutic Implications in Bacterial Infections - PEXACY International Journal of Pharmaceutical Sciencepexacy.com
38. 6 Amoxicillin Interaction You Should Know About - GoodRxgoodrx.com
39. Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TBcdn.clinicaltrials.gov
40. Amoxicillin rash in infectious mononucleosisccjm.org
41. Incidence of Rash After Amoxicillin Treatment in Children With Infectious Mononucleosispublications.aap.org
42. Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitizationncbi.nlm.nih.gov
43. β-Lactam Allergy and Cross-Reactivity: A Clinician’s Guidedovepress.com
44. Approach to beta-lactam allergy in critical care - EMCrit Projectemcrit.org
45. Cross-reactivity between amoxicillin and piperacillin–tazobactam in patients with amoxicillin allergy: A prospective study - ScienceDirectsciencedirect.com
46. Allergic Cross-reactivity of Select Antimicrobials Definitionhealth.ucdavis.edu
47. Evaluation and Management of Penicillin Allergy: A Review - PubMedpubmed.ncbi.nlm.nih.gov
48. Penicillin Allergy and Perioperative Anaphylaxisncbi.nlm.nih.gov
49. Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).cdn.clinicaltrials.gov
50. Amoxicillin and Oral Contraceptives Interaction: What You Need to Knowempathia.ai
51. Amoxicillin-Triggered Rash in Latent Epstein-Barr Virus Infection: A Case of Kawasaki Disease Mimicry in a Seven-Year-Old Girlncbi.nlm.nih.gov
52. Amoxicillin-potassium clavulanate interactions to avoidsinglecare.com
53. Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Testclinicaltrials.gov
54. A drug-resistant β-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potencyncbi.nlm.nih.gov
55. β-lactamase inhibitor combination Overview Amoxicillin isldh.la.gov
56. Clavulanic Acid: The Unsung Hero of β‑Lactam Antibioticsrxhero.pharmacologymentor.com
57. Amoxicillin–clavulanic acid: Antimicrobial Activity, Susceptibility, Administration and Dosage etc._Chemicalbookchemicalbook.com
58. PDB-101: Global Health: Antimicrobial Resistance: undefined: Amoxicillin Resistancepdb101.rcsb.org
59. Molecular basis of ampicillin resistance: combinatorial mechanisms and future strategieslink.springer.com
60. Penicillin Binding Protein - an overviewsciencedirect.com
61. Penicillin-binding proteins and β-lactam resistanceacademic.oup.com
62. Horizontal transfer of antibiotic resistance genes in clinical environmentscdnsciencepub.com
63. Multiplication of ampC upon Exposure to a Beta-Lactam Antibiotic Results in a Transferable Transposon in Escherichia colincbi.nlm.nih.gov
64. Cooperative antibiotic resistance facilitates horizontal gene transfernature.com
65. Synergistic effects of novel penicillin-binding protein 1A amino acid substitutions contribute to high-level amoxicillin resistance of Helicobacter pylorijournals.asm.org
66. Combined genomic-proteomic approach in the identification of Campylobacter coli amoxicillin-clavulanic acid resistance mechanism in clinical isolatesncbi.nlm.nih.gov
67. Clavulanic Acid - an overviewsciencedirect.com
68. Antibiotic resistance in gonorrheaen.wikipedia.org
69. Alexander Flemingbritannica.com
70. Alexander Flemingsciencehistory.org
71. The discovery of antibioticsreactgroup.org
72. wwwnc.cdc.govwwwnc.cdc.gov
73. Aminopenicillin - an overviewsciencedirect.com
74. Amoxicillinencyclopedia.com
75. amoxicillin · CDEKcdek.pharmacy.purdue.edu
76. Soluble forms of amoxicillin and treatment of animalsimage-ppubs.uspto.gov
77. Penicillin: 83 Years Ago Todaypublichealth.columbia.edu
78. Soluble forms of amoxicillin and treatment of animalsimage-ppubs.uspto.gov
79. Florey and Chain Develop Penicillin as an Antibioticebsco.com
80. The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Usewwwnc.cdc.gov
81. (PDF) One-pot, two-step enzymatic synthesis of amoxicillin by complexing with Zn2+researchgate.net
82. The role of 6-aminopenicillanic acid on the kinetics of amoxicillin enzymatic synthesis catalyzed by penicillin G acylase immobilized onto glyoxyl-agaroseresearchgate.net
83. Enzymatic synthesis of amoxicillin via a one-pot enzymatic hydrolysis and condensation cascade process in the presence of organic co-solvents - PubMedpubmed.ncbi.nlm.nih.gov
84. (PDF) Dynamic Modelling and Optimisation of the Batch Enzymatic Synthesis of Amoxicillinresearchgate.net
85. CN111518119A - Continuous amoxicillin crystallization process - Google Patentspatents.google.com
86. The effect of ultrasound on the crystallization-precipitation process of transforming sodium amoxicillin into amoxicillin trihydratencbi.nlm.nih.gov
87. Investigating the Role of Citric Acid as a Natural Acid on the Crystallization of Amoxicillin Trihydratepubs.acs.org
88. Green manufacturing of amoxicillin trihydrate: a malic acid-assisted crystallization framework enhanced by Taguchi–ANN optimizationpubs.rsc.org
89. Production of a crystalline salt of amoxicillinimage-ppubs.uspto.gov
90. Amoxicillin shortage update: What patients need to know in 2medfinder.com
91. amoxicillin shortage some forms of this common antibiotic in short supplyhealthline.com
92. Amoxicillin Suspension Shortage Resolvedrepublicpharma.com
93. Process for the production of 6-D-.alpha.-amino-p-hydroxyphenylacetamido penicillanic acidimage-ppubs.uspto.gov
94. Crystallization of Amoxicillin Trihydrate in the Presence of Degradation Productspubs.acs.org
95. US3980637A - Production of amoxicillin - Google Patentspatents.google.com
96. Companies report shortages of common childhood antibiotic amoxicillinthehill.com
97. Behind the Amoxicillin Shortage in US - Bloombergbloomberg.com
98. World Health Organization Model List of Essential Medicines 21st List 2019iccp-portal.org
99. Amoxicillin - Electronic Essential Medicines Listlist.essentialmeds.org
100. Manual for Procurement & Supply of Quality-Assured MNCH Commodities MODULE IIIghsupplychain.org
101. What you need to know about the 2022 amoxicillin shortagesinglecare.com
102. Amoxicillin is in short supply, federal health officials saynbcnews.com
103. Doctors, pharmacists coping with amoxicillin shortagecidrap.umn.edu
104. Amoxicillin and amoxicillin/clavulanic acid - supply shortageema.europa.eu
105. Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulationsncbi.nlm.nih.gov
106. Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trialjamanetwork.com
107. Shorter versus longer duration of Amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: a systematic review and meta-analysislink.springer.com
108. Shorter Versus Longer Antibiotic Treatment in Children With Community-Acquired Pneumonia: A Systematic Review With Meta-Analyses - PubMedpubmed.ncbi.nlm.nih.gov
109. Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Childrencdn.clinicaltrials.gov
110. Short-course Antibiotic Treatment for Community-acquired Alveolar Pneumonia in Ambulatory Childrenovid.com
111. Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Childrencdn.clinicaltrials.gov
112. Amoxicillin dosing and pharmacokinetics in obesity for the treatment of bacterial respiratory infection secondary to COVID-19: a systematic reviewrsdjournal.org
113. Pharmacokinetics, target attainment and outcomes of piperacillin/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysismedrxiv.org
114. Continuous beta-lactam infusion in critically ill patients: the clinical evidencencbi.nlm.nih.gov
115. Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing for Respiratory Tract Infections in Primary Care: Systematic Review and Meta-Analysis of Randomised Controlled Trialsncbi.nlm.nih.gov
116. Impact of adherence to procalcitonin antibiotic prescribing guideline recommendations for low procalcitonin levels on antibiotic usencbi.nlm.nih.gov
117. Amoxicillin dosing and pharmacokinetics in obesity for the ...rsdjournal.org